Effects of vatinoxan on cardiorespiratory function, fecal output and plasma drug concentrations in horses anesthetized with isoflurane and infusion of medetomidine.
Authors: Tapio H A, Raekallio M R, Mykkänen A K, Al-Ramahi D, Scheinin M, Hautajärvi H J, Männikkö S, Vainio O
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary: Vatinoxan and Medetomidine in Equine Anaesthesia Medetomidine constant rate infusions are a cornerstone of balanced anaesthesia in horses, yet their cardiovascular depression remains problematic for practitioners. Researchers used a crossover design in six healthy horses to compare isoflurane anaesthesia maintained with medetomidine alone versus medetomidine combined with vatinoxan, a peripheral α₂-adrenoceptor antagonist intended to mitigate these effects, measuring haemodynamic variables, blood gases, and postoperative recovery parameters over 60 minutes of steady-state anaesthesia. Whilst vatinoxan preserved cardiac index and oxygen delivery index substantially better than medetomidine monotherapy—particularly at 20 minutes, where cardiac index was 73±18 versus 39±2 mL/min/kg (P=0.009)—the drug induced clinically significant hypotension requiring greater dobutamine support (P=0.018). Despite these concerning pressor effects, heart rate and arterial pressures remained within acceptable clinical ranges in both groups, and fecal output and dexmedetomidine concentrations showed no differences. For equine anaesthetists, vatinoxan presents a paradox: improved cardiac performance at the cost of additional vasoactive drug requirements, suggesting its role in clinical practice requires further evaluation before wider adoption.
Read the full abstract on PubMed
Practical Takeaways
- •While vatinoxan improved cardiac performance and oxygen delivery during medetomidine-isoflurane anesthesia, it caused hypotension requiring vasopressor support—use requires careful hemodynamic monitoring and is not recommended as routine premedication without further safety studies
- •Medetomidine CRI alone resulted in clinically acceptable heart rates and blood pressures but significantly reduced cardiac output and oxygen delivery compared to vatinoxan co-administration
- •Further research is needed to establish optimal dosing and safety protocols if vatinoxan is considered to mitigate medetomidine's cardiovascular side effects in equine anesthesia
Key Findings
- •Vatinoxan (peripheral α2-adrenoceptor antagonist) at 140 μg/kg IV improved cardiac index and oxygen delivery index compared to medetomidine alone at 20 minutes (CI: 73±18 vs 39±2 mL/min/kg, P=0.009; DO2I: 15.3±4.8 vs 7.4±1.2 mL/min/kg, P=0.014)
- •Vatinoxan premedication induced hypotension requiring significantly more dobutamine to maintain normotension (P=0.018) compared to medetomidine alone
- •No differences in fecal output or plasma dexmedetomidine concentrations were observed between medetomidine with or without vatinoxan